Article

PD-L1 status on Circulating Tumor Cells: A Promising Predictor in Advanced Lung Cancer with PD-1/PD-L1 immunotherapies

2025-11-18

Abstract excerpt

<title>Abstract</title> <p> Background Tumor heterogeneity and invasive sampling limit traditional tissue-based PD-L1 testing in advanced lung cancer. We explored a non-invasive alternative by assessing PD-L1 expression on circulating tumor cells (CTC PD-L1) via liquid biopsy to predict immunotherapy outcomes. Methods Fifty-two advanced lung cancer patients were recruited and 38 individuals received combination...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f1c947a8-5d0d-58ba-8591-b8f19c095f1f
DOI: 10.21203/rs.3.rs-7920255/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PD-L1 status on Circulating Tumor Cells: A Promising Predictor in Advanced Lung Cancer with PD-1/PD-L1 immunotherapiesDOI 10.21203/rs.3.rs-7920255/v1Read

Temporal Effect on PD-L1 Detection and Novel Insights Into Its Clinical Implications in Non-Small Cell Lung Cancer.Semantic proximity Read

Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancerSemantic proximity Read

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity Read

Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity Read

A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity Read

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.Semantic proximity Read

PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?Semantic proximity Read

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read